CD44 and cancer: Other cell surface heparan sulfate proteoglycans (HSPG), such as syndecans, perlecans, and glypicans have been shown to promote cancer pathogenesis (including ovarian) and expression changes of such HSPGs have been correlated with poorer patient outcomes [78–80].